Larimar Therapeutics, Inc.

NasdaqGM:LRMR Stock Report

Market Cap: US$502.1m

Larimar Therapeutics Past Earnings Performance

Past criteria checks 0/6

Larimar Therapeutics's earnings have been declining at an average annual rate of -2.7%, while the Biotechs industry saw earnings growing at 15.5% annually.

Key information

-2.7%

Earnings growth rate

39.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-19.5%
Net Marginn/a
Last Earnings Update31 Mar 2024

Recent past performance updates

No updates

Recent updates

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21
We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Dec 15

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Dec 08

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

Nov 16

Larimar Therapeutics reports Q3 results

Nov 10

Revenue & Expenses Breakdown

How Larimar Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:LRMR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 240-451536
31 Dec 230-371428
30 Sep 230-331424
30 Jun 230-331323
31 Mar 230-331223
31 Dec 220-351224
30 Sep 220-351223
30 Jun 220-441232
31 Mar 220-471235
31 Dec 210-511238
30 Sep 210-561343
30 Jun 210-491436
31 Mar 210-481335
31 Dec 200-421131
30 Sep 200-34926
30 Jun 200-33627
31 Mar 200-25422
31 Dec 190-23221

Quality Earnings: LRMR is currently unprofitable.

Growing Profit Margin: LRMR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LRMR is unprofitable, and losses have increased over the past 5 years at a rate of 2.7% per year.

Accelerating Growth: Unable to compare LRMR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LRMR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).


Return on Equity

High ROE: LRMR has a negative Return on Equity (-19.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.